US 12,071,474 B2
Monoclonal antibodies against alpha-synuclein fibrils
Kelvin C. Luk, Philadelphia, PA (US); Virginia M. Y. Lee, Philadelphia, PA (US); John Q. Trojanowski, Philadelphia, PA (US); Kurt R. Brunden, Media, PA (US); and Dustin Covell, Philadelphia, PA (US)
Assigned to The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed by The Trustees of the University of Pennsylvania, Philadelphia, PA (US)
Filed on Jan. 10, 2022, as Appl. No. 17/572,309.
Application 17/572,309 is a continuation of application No. 16/609,885, granted, now 11,220,538, previously published as PCT/US2018/030436, filed on May 1, 2018.
Claims priority of provisional application 62/492,663, filed on May 1, 2017.
Prior Publication US 2022/0135661 A1, May 5, 2022
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/18 (2006.01); A61K 9/00 (2006.01); A61K 39/00 (2006.01); A61P 25/28 (2006.01); G01N 33/577 (2006.01); G01N 33/68 (2006.01)
CPC C07K 16/18 (2013.01) [A61K 9/0029 (2013.01); A61P 25/28 (2018.01); G01N 33/577 (2013.01); G01N 33/6896 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/34 (2013.01); C07K 2317/565 (2013.01); C07K 2317/92 (2013.01)] 7 Claims
 
1. A method of treating a synucleopathic disease in a subject in need thereof, the method comprising administering to the subject a therapeutically effective amount of the isolated monoclonal antibody, which comprises a light chain variable region (VL) and a heavy variable region (VH),
wherein the VL comprises:
a CDR1 region comprising the amino acid sequence of SEQ ID NO: 21;
a CDR2 region comprising the amino acid sequence of SEQ ID NO: 22; and
a CDR3 region comprising the amino acid sequence of SEQ ID NO: 23, and
wherein the VH comprises
a CDR1 region comprising the amino acid sequence of SEQ ID NO: 26;
a CDR2 region comprising the amino acid sequence of SEQ ID NO: 27; and
a CDR3 region comprising the amino acid sequence of SEQ ID NO: 28.